Market Overview

Credit Suisse Sees A Potential Merger Or Acquisition In Macrocure's Future


Credit Suisse analyst Mathew Keeler downgraded Macrocure Ltd (NASDAQ: MCUR) to Underperform from Neutral and kept a price objective of $1.00. However, the brokerage expects a possible acquisition or merger in the upcoming years.

The analyst pointed out the recent strength in share price and sees more downside pressures to hurt the stock in the absence of any fresh catalyst. Credit Suisse doesn't expect any change in the outlook of Macrocure's pipeline.

"We continue to expect that MCUR is unlikely to move forward with additional CureXcell clinical programs given the phase 3 results shared late last year and a lack of funding. It is unclear to us at this point what MCUR's next steps will be, but we see a merger with or acquisition by another company (for the purpose of transfer of intellectual property or cash) as a potential next step," the analyst explained in a note.

The brokerage said its price target is based on the company's balance sheet cash and equivalents of $27.9 million minus operating expenses of the immediate term. The analyst also pointed out key risks to his call stating that the company's intellectual property value could interest another company to make an acquisition proposal. That would have the potential to exceed his $1 price objective.

The stock traded 3. percent down on Monday.

Latest Ratings for MCUR

Jul 2016DowngradesNeutralUnderperform
Aug 2015DowngradesOutperformNeutral
Aug 2015DowngradesOutperformNeutral

View More Analyst Ratings for MCUR
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color News Downgrades Analyst Ratings


Related Articles (MCUR)

View Comments and Join the Discussion!

Latest Ratings

ELMDDougherty & Co.Initiates Coverage On12.0
MRNSCantor FitzgeraldAssumes7.0
MNRLCapital One FinancialInitiates Coverage On23.0
SONVertical GroupUpgrades
UNPMorgan StanleyMaintains136.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Varian Medical Gets FDA Registration For Claymount Optica Collimators

Is Alex Gurevich Still Short Cash?